Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2008
This is a multicenter, randomized, open-label study. 40 patients will be followed for a period of 12 months. All consented and enrolled patients will receive either 0.5mg or 2.0mg of intravitreal ranibizumab injection.
Epistemonikos ID: b9a6457087788080030dda2f68c4744c5f97b102
First added on: May 05, 2024